

Josep Maria Auge Fradera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/662034/publications.pdf>

Version: 2024-02-01

56
papers

2,282
citations

236925

25
h-index

214800

47
g-index

58
all docs

58
docs citations

58
times ranked

3419
citing authors

#	ARTICLE	IF	CITATIONS
1	Analytical and clinical evaluation of DiaSorin Liaison® Calprotectin fecal assay adapted for serum samples. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24258.	2.1	6
2	Evaluating the Potential of Polygenic Risk Score to Improve Colorectal Cancer Screening. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1305-1312.	2.5	4
3	Faecal immunochemical tests for haemoglobin: Analytical challenges and potential solutions. <i>Clinica Chimica Acta</i> , 2021, 517, 60-65.	1.1	17
4	Agreement of amyloid PET and CSF biomarkers in a clinical cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
5	Contribution of CSF biomarkers to early-onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures. <i>Human Brain Mapping</i> , 2020, 41, 2004-2013.	3.6	22
6	Evaluación del ensayo enhanced estradiol (eE2) en el analizador Atellica IM 1600 de Siemens. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2020, 1, .	0.2	0
7	Performance evaluation of Siemens Atellica enhanced estradiol assay. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2020, 1, .	0.2	0
8	Clinical applicability of diagnostic biomarkers in early-onset cognitive impairment. <i>European Journal of Neurology</i> , 2019, 26, 1098-1104.	3.3	20
9	Changes in FIT values below the threshold of positivity and short-term risk of advanced colorectal neoplasia: Results from a population-based cancer screening program. <i>European Journal of Cancer</i> , 2019, 107, 53-59.	2.8	21
10	Impacto de una intervención de Atención Primaria en el programa de detección precoz de cáncer colorrectal. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 351-361.	0.5	1
11	An evaluation of the SENTiFIT 270 analyser for quantitation of faecal haemoglobin in the investigation of patients with suspected colorectal cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 625-633.	2.3	11
12	Colorectal cancer after negative colonoscopy in fecal immunochemical test-positive participants from a colorectal cancer screening program. <i>Endoscopy International Open</i> , 2018, 06, E1140-E1148.	1.8	16
13	Relationship Between CA 19.9 and the Lewis Phenotype: Options to Improve Diagnostic Efficiency. <i>Anticancer Research</i> , 2018, 38, 5883-5888.	1.1	35
14	Reassessment colonoscopy to diagnose serrated polyposis syndrome in a colorectal cancer screening population. <i>Endoscopy</i> , 2017, 49, 44-53.	1.8	35
15	Utility of proGRP as a tumor marker in the medullary thyroid carcinoma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 441-446.	2.3	10
16	Association between socioeconomic deprivation and colorectal cancer screening outcomes: Low uptake rates among the most and least deprived people. <i>PLoS ONE</i> , 2017, 12, e0179864.	2.5	24
17	Mo1701 Gastrointestinal Events After a Negative Colonoscopy in FIT-Positive Participants in an Organized, Population-Based Colorectal Cancer Screening Program. <i>Gastroenterology</i> , 2016, 150, S756.	1.3	1
18	Impact of age- and gender-specific cut-off values for the fecal immunochemical test for hemoglobin in colorectal cancer screening. <i>Digestive and Liver Disease</i> , 2016, 48, 542-551.	0.9	23

#	ARTICLE	IF	CITATIONS
19	Clinical utility of one versus two faecal immunochemical test samples in the detection of advanced colorectal neoplasia in symptomatic patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 125-32.	2.3	29
20	Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 427-437.	5.6	139
21	Faecal haemoglobin concentrations do vary across geography as well as with age and sex: ramifications for colorectal cancer screening. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, e235-7.	2.3	10
22	The influence of prostate volume in prostate health index performance in patients with total PSA lower than 10 ¹ / ₄ g/L. <i>Clinica Chimica Acta</i> , 2014, 436, 303-307.	1.1	28
23	Clinical utility of %p2PSA and prostate health index in the detection of prostate cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 1347-55.	2.3	43
24	Variability of assay methods for total and free PSA after WHO standardization. <i>Tumor Biology</i> , 2014, 35, 1867-1873.	1.8	24
25	Risk Stratification for Advanced Colorectal Neoplasia According to Fecal Hemoglobin Concentration in a Colorectal Cancer Screening Program. <i>Gastroenterology</i> , 2014, 147, 628-636.e1.	1.3	94
26	Serum 25-hydroxyvitamin D3 levels and vitamin D receptor variants in melanoma patients from the Mediterranean area of Barcelona. <i>BMC Medical Genetics</i> , 2013, 14, 26.	2.1	24
27	PCA3 in the detection and management of early prostate cancer. <i>Tumor Biology</i> , 2013, 34, 1337-1347.	1.8	48
28	Circulating levels of HER-2/neu oncoprotein in breast cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 5-21.	2.3	27
29	CA 19â€™9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer. <i>Tumor Biology</i> , 2012, 33, 799-807.	1.8	42
30	Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site. <i>Tumor Biology</i> , 2012, 33, 463-474.	1.8	52
31	HE4 a novel tumor marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. <i>Tumor Biology</i> , 2011, 32, 1087-1095.	1.8	133
32	Comparison of Serum Human Epididymis Protein 4 with Cancer Antigen 125 as a Tumor Marker in Patients with Malignant and Nonmalignant Diseases. <i>Clinical Chemistry</i> , 2011, 57, 1534-1544.	3.2	167
33	Diagnostic relevance of circulating biomarkers in patients with lung cancer. <i>Cancer Biomarkers</i> , 2010, 6, 163-178.	1.7	75
34	Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. <i>Tumor Biology</i> , 2010, 31, 171-180.	1.8	61
35	Prospective Evaluation of Carcinoembryonic Antigen (CEA) and Carbohydrate Antigen 15.3 (CA 15.3) in Patients with Primary Locoregional Breast Cancer. <i>Clinical Chemistry</i> , 2010, 56, 1148-1157.	3.2	70
36	Colonic Penetration after Kugel Patch Inguinal Hernia Repair. <i>Japanese Journal of Gastroenterological Surgery</i> , 2010, 43, 90-94.	0.1	4

#	ARTICLE	IF	CITATIONS
37	Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer. <i>Endocrine-Related Cancer</i> , 2009, 16, 311-317.	3.1	28
38	Serum Matrilysin Levels Predict Outcome in Curatively Resected Colorectal Cancer Patients. <i>Annals of Surgical Oncology</i> , 2009, 16, 1412-1420.	1.5	21
39	Usefulness of Serum Tumor Markers, Including Progastrin-Releasing Peptide, in Patients with Lung Cancer: Correlation with Histology. <i>Tumor Biology</i> , 2009, 30, 121-129.	1.8	94
40	The Role of MMP7 and Its Cross-Talk with the FAS/FASL System during the Acquisition of Chemoresistance to Oxaliplatin. <i>PLoS ONE</i> , 2009, 4, e4728.	2.5	68
41	Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access [®] BR Monitor assay on the UniCel [®] DxI 800 Immunoassay System. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 612-22.	2.3	10
42	Alternative antibody for the detection of CA19-9 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access [®] GI Monitor assay on the UniCel [®] DxI 800 Immunoassay System. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 600-11.	2.3	15
43	Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access [®] OV Monitor assay on the UniCel [®] DxI 800 Immunoassay System. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 588-99.	2.3	10
44	Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as Tumor Markers in Patients with Lung Cancer: Comparison with CYFRA 21-1, CEA, SCC and NSE. <i>Tumor Biology</i> , 2008, 29, 371-380.	1.8	107
45	Correlation of matrilysin levels and IGF-1/IGFBP-3 ratio with acquired chemo-resistance in advanced colorectal cancer (ACRC). <i>Journal of Clinical Oncology</i> , 2008, 26, 15023-15023.	1.6	0
46	Pharmacodynamic study of soluble FAS (sFAS) and FASL (sFASL), in patients (pts) with advanced colorectal cancer (ACRC) after irinotecan and cetuximab treatment in third-line therapy: Results of HCB-05 [®] 01 trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 22046-22046.	1.6	0
47	Serum Vascular Endothelial Growth Factor as a Predictive Factor in Metronomic (Weekly) Paclitaxel Treatment for Advanced Head and Neck Cancer. <i>JAMA Otolaryngology</i> , 2007, 133, 1143.	1.2	20
48	Prognostic Implications of Protein S-100 β ; Serum Levels in the Clinical Outcome of High-Risk Melanoma Patients. <i>Tumor Biology</i> , 2007, 28, 264-272.	1.8	15
49	Serum vascular endothelial growth factor as prognostic factor in metronomic weekly paclitaxel treatment for patients with advanced head and neck cancer refractory to platinum-based chemotherapy. <i>Radiotherapy and Oncology</i> , 2007, 82, S33.	0.6	0
50	Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. <i>International Journal of Cancer</i> , 2007, 121, 1066-1071.	5.1	90
51	Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1391-1398.	0.8	31
52	Serum Protein S-100 Predicts Clinical Outcome in Patients with Melanoma Treated with Adjuvant Interferon α Comparison with Tyrosinase RT-PCR. <i>Oncology</i> , 2005, 68, 341-349.	1.9	18
53	S-100 β and MIA in advanced melanoma in relation to prognostic factors. <i>Anticancer Research</i> , 2005, 25, 1779-82.	1.1	16
54	Pro-Gastrin-Releasing Peptide in Patients with Benign and Malignant Diseases. <i>Tumor Biology</i> , 2004, 25, 56-61.	1.8	44

#	ARTICLE	IF	CITATIONS
55	ProGRP: a new biomarker for small cell lung cancer. <i>Clinical Biochemistry</i> , 2004, 37, 505-511.	1.9	118
56	Tumor Markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in Patients with Non-Small Cell Lung Cancer as an Aid in Histological Diagnosis and Prognosis. <i>Tumor Biology</i> , 2003, 24, 209-218.	1.8	233